Researchers at the Vision Center at Children's Hospital Los Angeles are making significant strides toward a potential treatment for blue cone monochromacy (BCM), a rare, inherited vision disorder linked to the X chromosome. The team, led by Dr. Aaron Nagiel, has received a $4.7 million grant from the California Institute for Regenerative Medicine to prepare for a Phase 1 clinical trial of BGTF-027, a novel gene therapy.
Blue cone monochromacy is caused by mutations in the red and green opsin gene cluster (OPN1LW and OPN1MW), leading to severe vision loss, color blindness, extreme light sensitivity, and involuntary eye movements. Currently, there is no approved treatment for this condition, which affects fewer than 1 in 100,000 people.
BGTF-027, formerly known as ADVM-062, was developed by Adverum Biotechnologies and licensed to the Blue Gen Therapeutics Foundation. It is an intravitreal gene therapy designed to deliver a functional copy of the long-wavelength-sensitive (L-opsin) protein directly to the cone photoreceptors. Unlike other gene therapies that require invasive subretinal surgery, BGTF-027 can be administered via an injection into the vitreous cavity of the eye, potentially allowing for outpatient treatment with less recovery time.
Over the next 18 months, the research team will finalize the clinical trial protocol and prepare the investigational new drug application for the FDA. If successful, this therapy could slow disease progression and restore visual function for patients with BCM.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.